Characterizing a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec from the Phase 3 Benegene-2 Study Who Returned to Factor IX Prophylaxis

Frenzel, LaurentKavakli, KaanKlamroth, RobertChiou, Shyh-ShinShapiro, Amy D.Sun, PenglingFuiman, Joanne2024-08-312024-08-3120230006-49711528-0020https://doi.org/10.1182/blood-2023-181223https://hdl.handle.net/11454/10535665th Annual Meeting of the American-Society-of-Hematology (ASH) -- DEC 09-12, 2023 -- San Diego, CA[Abstarct Not Available]en10.1182/blood-2023-181223info:eu-repo/semantics/openAccessCharacterizing a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec from the Phase 3 Benegene-2 Study Who Returned to Factor IX ProphylaxisConference Object142WOS:001159306708229Q1